Literature DB >> 15508100

Hepatocellular carcinoma: summary and recommendations.

Jay H Hoofnagle1.   

Abstract

Entities:  

Mesh：

Year:  2004        PMID： 15508100     DOI： 10.1053/j.gastro.2004.09.047

Source DB:  PubMed          Journal:  Gastroenterology        ISSN： 0016-5085            Impact factor:   22.682


× No keyword cloud information.
  14 in total

1.  Complication rates of ablation therapies for hepatocellular carcinoma: a difficult comparison with an easy solution.

Authors:  V Arienti; S Pretolani
Journal:  Gut       Date:  2006-08       Impact factor: 23.059

Review 2.  Pathophysiological basis for antioxidant therapy in chronic liver disease.

Authors:  Jesús Medina; Ricardo Moreno-Otero
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 3.  Host functions used by hepatitis B virus to complete its life cycle: Implications for developing host-targeting agents to treat chronic hepatitis B.

Authors:  Bidisha Mitra; Roshan J Thapa; Haitao Guo; Timothy M Block
Journal:  Antiviral Res       Date:  2018-08-24       Impact factor: 5.970

4.  Hepatocellular carcinoma in HIV-infected patients: check early, treat hard.

Authors:  Massimiliano Berretta; Elisa Garlassi; Bruno Cacopardo; Alessandro Cappellani; Giovanni Guaraldi; Stefania Cocchi; Paolo De Paoli; Arben Lleshi; Immacolata Izzi; Augusta Torresin; Pietro Di Gangi; Antonello Pietrangelo; Mariachiara Ferrari; Alessandra Bearz; Salvatore Berretta; Guglielmo Nasti; Fabrizio Di Benedetto; Luca Balestreri; Umberto Tirelli; Paolo Ventura
Journal:  Oncologist       Date:  2011-08-25

5.  Thymoquinone suppression of the human hepatocellular carcinoma cell growth involves inhibition of IL-8 expression, elevated levels of TRAIL receptors, oxidative stress and apoptosis.

Authors:  Abdelkader E Ashour; Adel R Abd-Allah; Hesham M Korashy; Sabry M Attia; Abdelrahman Z Alzahrani; Quaiser Saquib; Saleh A Bakheet; Hala E Abdel-Hamied; Shazia Jamal; Arun K Rishi
Journal:  Mol Cell Biochem       Date:  2014-01-08       Impact factor: 3.396

6.  A case of hepatocellular carcinoma with multiple lung, spleen, and remnant liver metastasis successfully treated by combination chemotherapy with the novel oral DPD-inhibiting chemotherapeutic drug S-1 and interferon-alpha.

Authors:  Masato Nakamura; Hiroaki Nagano; Hiroshi Wada; Takehiro Noda; Hideo Ota; Bazarragchaa Damdinsuren; Shigeru Marubashi; Atsushi Miyamoto; Yutaka Takeda; Koji Umeshita; Keizo Dono; Morito Monden
Journal:  J Gastroenterol       Date:  2006-12-08       Impact factor: 7.527

7.  The Importance of Safety-Net Hospitals in Emergency General Surgery.

Authors:  Vikrom K Dhar; Young Kim; Koffi Wima; Richard S Hoehn; Shimul A Shah
Journal:  J Gastrointest Surg       Date:  2018-07-23       Impact factor: 3.452

8.  Identification of biomarkers associated with the development of hepatocellular carcinoma in CuZn superoxide dismutase deficient mice.

Authors:  Sailaja Elchuri; Mohammed Naeemuddin; Orr Sharpe; William H Robinson; Ting-Ting Huang
Journal:  Proteomics       Date:  2007-06       Impact factor: 3.984

9.  Reduced expression of Jak-1 and Tyk-2 proteins leads to interferon resistance in hepatitis C virus replicon.

Authors:  Sidhartha Hazari; Lizeth Taylor; Salima Haque; Robert F Garry; Sander Florman; Ronald Luftig; Frederic Regenstein; Srikanta Dash
Journal:  Virol J       Date:  2007-09-18       Impact factor: 4.099

10.  National trends and disparities in the incidence of hepatocellular carcinoma, 1998-2003.

Authors:  Faruque Ahmed; Joseph F Perz; Sandy Kwong; Patricia M Jamison; Carol Friedman; Beth P Bell
Journal:  Prev Chronic Dis       Date:  2008-06-15       Impact factor: 2.830
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.